Roche’s Breast Cancer Strategy Paying Off, But Diversification Difficult
This article was originally published in The Pink Sheet Daily
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.
You may also be interested in...
Roche Digs In To Early Breast Cancer With New Perjeta Approvals
Better than expected FDA labeling for rising star Perjeta in neoadjuvant (before surgery) and adjuvant (after surgery) breast cancer could boost sales greatly beyond expectations, some analysts say.
Roche: Slow And Steady Wins The Race
The firm got off to a solid start in 2016, which should see its biggest launches in years, but its core strength remains executing long-term management of its key franchises.
Roche Defends HER2 Franchise After MARIANNE Failure
MARIANNE frontline breast cancer trial failure was a blow, but HER2 franchise remains strong overall, particularly with the survival results from the CLEOPATRA study and other key studies due to report, company argues.